Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 15, 2024

Ruxolitinib With Standard Chemotherapy as a Front-Line Neoadjuvant Treatment for Advanced Ovarian Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
J. Clin. Oncol 2024 May 22;[EPub Ahead of Print], CN Landen, RJ Buckanovich, MW Sill, RS Mannel, JL Walker, PA DiSilvestro, CA Mathews, DG Mutch, ML Hernandez, LP Martin, E Bishop, SE Gill, ME Gordinier, RA Burger, C Aghajanian, JF Liu, KN Moore, MA Bookman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading